Flt-3 Ligand/FLT3L Antibody [Biotin]

• Reactivity: Hu
• Applications: WB, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

Flt-3 Ligand/FLT3L Antibody [Biotin] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Flt-3 Ligand/FLT3L
  Thr27-Pro185
  Accession # AAA17999
• Specificity: Detects human Flt-3 Ligand/FLT3L in ELISAs and Western blots. In sandwich immunoassays, less than 0.05% cross-reactivity with recombinant human (rh) PlGF, recombinant mouse Flt-3 Ligand/FLT3L, rhVEGF and rhFlt-1 Fc chimera is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FLT3LG
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Human Flt-3 Ligand Antibody (Catalog # MAB608)
  ELISA Detection: Human Flt-3 Ligand Biotinylated Antibody (Catalog # BAF308)
  Standard: Recombinant Human Flt-3 Ligand (Catalog # 308-FKN)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Flt-3 Ligand/FLT3L Antibody [Biotin]

• FL
• FLG3L
• Flt3 ligand
• Flt-3 Ligand
• Flt3L
• FLT3LG
• fms-related tyrosine kinase 3 ligand
• SL cytokine

Background

Flt-3 Ligand, also known as FL, is an alpha -helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1 - 3). Mature human Flt-3 Ligand consists of a 158 amino acid (aa) extracellular domain (ECD) with a cytokine-like domain and a juxtamembrane tether region, a 21 aa transmembrane segment, and a 30 aa cytoplasmic tail (4 - 7). Within the ECD, human Flt-3 Ligand shares 71% and 65% aa sequence identity with mouse and rat Flt-3 Ligand, respectively. Human and mouse Flt-3 Ligand show cross-species activity (4 - 6). Flt-3 Ligand is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts (1, 8). Each 36 kDa chain carries approximately 12 kDa of N- and O-linked carbohydrates (8). Alternate splicing and proteolytic cleavage of the transmembrane form can generate a soluble 30 kDa fragment that includes the cytokine domain (4, 8). Alternate splicing of human Flt-3 Ligand also generates membrane-associated isoforms that contain either a truncated cytoplasmic tail or an 85 aa substitution following the cytokine domain (4, 5, 8). Both transmembrane and soluble Flt-3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2 (3, 4, 6, 7). Flt-3 Ligand induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2, 9). It synergizes with IL-3, GM-CSF, and SCF to promote the mobilization and myeloid differentiation of hematopoietic stem cells (4 - 6). It cooperates with IL-2, -6, -7, and -15 to induce NK cell development and with IL-3, -7, and -11 to induce terminal B cell maturation (1, 10). Animal studies also show Flt‑3 Ligand to reduce the severity of experimentally induced allergic inflammation (11).

1. Wodnar-Filipowicz, A. (2003) News Physiol. Sci. 18:247.
2. Dong, J. et al. (2002) Cancer Biol. Ther. 1:486.
3. Gilliland, D.G. and J.D. Griffin (2002) Blood 100:1532.
4. Hannum, C. et al. (1994) Nature 368:643.
5. Lyman, S.D. et al. (1994) Blood 83:2795.
6. Lyman, S.D. et al. (1993) Cell 75:1157.
7. Savvides, S.N. et al. (2000) Nat. Struct. Biol. 7:486.
8. McClanahan, T. et al. (1996) Blood 88:3371.
9. Diener, K.R. et al. (2008) Exp. Hematol. 36:51.
10. Farag, S.S. and M.A. Caligiuri (2006) Blood Rev. 20:123.
11. Edwan, J.H. et al. (2004) J. Immunol. 172:5016.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Flt-3 Ligand/FLT3L Antibody (BAF308)(4)

Publications using BAF308

• Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, Pring J, Pack M, Buckley N, Matei I, Lyden D, Green J, Hawthorne T, Marsh H, Yellin M, Davis T, Keler T, Schlesinger S Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant, 2015-04-27;50(7):924-30. 2015-04-27 [PMID: 25915810] (ELISA Development (Detection), Human)
• Kamila Zurkova, Petr Hainz, Jitka Krystofova, Luda Kutinova, Miloslav Sanda, Sarka Nemeckova Attenuation of vaccinia virus by the expression of human Flt3 ligand Virology Journal 12/1/2010 [PMID: 20504356]
• Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. J. Virol., 2006-08-01;80(15):7676-87. 2006-08-01 [PMID: 16840346] (Western Blot, Human)
• Sailaja G, Husain S, Nayak BP, Jabbar AM Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand. J. Immunol., 2003-03-01;170(5):2496-507. 2003-03-01 [PMID: 12594275] (Western Blot, Human)

Bioinformatics

• Gene Symbol: FLT3LG
• Uniprot:
  • AAA17999()